Arsenal Biosciences, Inc.
Biotechnology
Arsenal Biosciences, Inc. is a clinical-stage biotech company specializing in programmable cell therapies for cancer treatment. By leveraging advanced computational and engineering techniques, ArsenalBio aims to develop innovative therapies targeting solid tumors. Their approach integrates diverse scientific expertise to create optimal medicines that improve patient outcomes.
Founded: 2019
Kenneth Drazan Co-Founder, Chief Executive Officer |
Tarjei Mikkelsen, Ph.D. Chief Technology Officer |
Susie Jun, Ph.D. Chief Medical Officer |
Nick Haining Co-Founder, Chief Scientific Officer |
Bee Nguyen Chief People Officer |
Tim Sirichoke Chief Technology Operations Officer |
ArsenalBio announced that it has been named to the Endpoints 11, one of the 11 top biotechs of 2023. This is an annual honor selected by the editors of Endpoints News for the most promising and ambitious early-stage companies in the biotech industry.
ArsenalBio announced that it will present preclinical data on its ICT cell therapies, AB-1015 and AB-2100, in an oral abstract session and three posters at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, Calif., May 16-20, 2023.
ArsenalBio announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023. These data demonstrate the company’s continued progress towards the enhancement and clinical development of its unique integrated circuit T cell approach for diseases beyond ovarian cancer, including kidney cancer and other solid tumors.
ArsenalBio announced a multi-year collaboration with Genentech, a member of the Roche Group. The companies will deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T cells, to identify critical success circuits in T cell-based therapies.
ArsenalBio announced the close of a $220 million Series B financing round.